Navigation Links
American donors put faith (and dollars) in TAU cancer research
Date:11/13/2007

Will the cure for cancer have a Made In Israel stamp on it? American donors to the Israel Cancer Research Fund (ICRF) think there is a very good chance it could.

In September 2007, the ICRF gave a $350,000 seven-year grant to Tel Aviv Universitys Prof. Yossi Shiloh from the Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine. The fund donated tens of thousands more to eight other researchers at the university in a vote of confidence.

This year, awards totalling $1.65 million were announced at the home of U.S. Ambassador to Israel Richard Jones on September 5, 2007. Tel Aviv University received more than 10% of the overall grants. Ambassador Jones's home was an appropriate venue for the ceremony, as the event marked over 30 years of support for Israeli cancer research by the North American group.

At the ceremony, Prof. Shiloh commented on the fertile ground of cancer collaboration between the U.S. and Israel. Tonight we are guests at the home of the United States Ambassador to Israel. Holding this event here means more than just having a great venue for the reception. It signifies the strengthening of the scientific ties between the United States and Israel."

He added, Most Israeli scientists have spent some part of their career in the U.S. Our ties with American science and American funding agencies are now stronger than ever, and collaborative projects nourish the scientific soil in both countries.

Prof. Shiloh, who received his post-doctoral education from Harvard University, made his first breakthrough in cancer research in 1995 when he discovered the gene for the rare genetic disease ataxia-telangiectasia (A-T). He remarks, A-T is a very complex disease, involving neuronal degeneration, immunodeficiency, extreme radiation sensitivity and a striking predisposition to cancer. It was clear from the start that understanding A-T would open a window to many medical problems, not the least of which is the genetic predisposition to cancer.

The 1995 discovery was hailed by the prestigious American journal Science as the medical equivalent of the Rosetta Stone in deciphering the biochemical mysteries of cancer. Since then, Prof. Shiloh's lab has made several seminal discoveries about the function of the A-T gene, especially in its role in defending the living cell from the consequences of radiation damage. This research has paved the way for a more accurate diagnosis of the disease in patients around the world and has led to new directions in the search for potentially effective treatments.

Prof. Shilohs research is phenomenal, remarks Leah Susskind, an ICRF chairperson emeritus from New York. He is just out of this world. Listening to him explaining his research made my heart tick. I should add that we find only the top, top scientists to benefit from our fund, and Prof. Shiloh from Tel Aviv University is definitely one of them.

Although most of the donors to the ICRF prefer to remain anonymous, Susskind says that those who are pouring dollars into Israeli research are not just Jewish supporters of Israel. An unusual number of Christian North Americans, some of whom have benefited from Israeli-developed cancer therapies directly, are also keen on giving to the fund.

Israeli research teams have developed some of the most important cancer therapies used by Americans today. The most well-known examples include Doxil, for breast and ovarian cancer; Gleevec, used against leukemia; the key tumor suppressor p53; and Velcade, for the treatment of multiple myeloma. But Israel isnt the only thing these treatments have in common -- they were all funded during some part of their development cycle by the ICRF.

Concludes Prof. Shiloh, All of us at Israeli universities feel the enormous contribution the ICRF has made to cancer research here. Since 1975, it has distributed no less than $35 million in grants to Israeli investigators, clearly shaping the landscape of cancer research in Israel. This is research that not only impacts the people of the region, but directly impacts the lives of Americans and people everywhere.


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University  
Source:Eurekalert

Related medicine news :

1. Many Older Americans Have Active Sex Lives
2. Despite grumbling, most Americans say they are happy at work
3. Record Number of Americans Lack Health Insurance
4. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
5. AUDIO from Medialink and Pfizer: Number of Uninsured Americans Grows to 47 Million
6. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
7. Novo Nordisk Appoints New Leader of North American Business
8. Amid Improving Life Expectancy Rates, Risk of Premature Death is Still Significant for Americans, New Study Shows
9. Primary biliary cirrhosis more severe in African-American and Hispanic patients
10. AOA President Calls on Congress to Reauthorize SCHIP and Take Action to Ensure Health Care Coverage for All Americans
11. American Chemical Societys Weekly Presspac -- Sept. 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
American donors put faith (and dollars) in TAU cancer research
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that services the ... Eastern Michigan last Friday in order to aid in the Flint water crisis. In ... a facility located in Clio, only 15 miles away from Flint. , “We have ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand ... within Healthcare, recently partnered with Heart City Health Center to improve ... 23 years, Heart City Health Center has provided the Elkhart community with access ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... 10 ... Brand. There were three leading bottled water brand owners that topped the list as ... enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged to ... shows that the Goal Attainment Scale (GAS) captures 20% more change in outcomes ... more about the Goal Attainment Scale, Education Resources Inc. is offering a course ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... and PITTSBURGH, Feb. 10, 2016 Mylan N.V. (NASDAQ, ... quarter and year ended December 31, 2015. ... Full year adjusted total revenues of $9.45 billion, up ... year; GAAP total revenues of $9.43 billion. Excluding the ... markets specialty and branded generics business (the "EPD Business"), ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
(Date:2/10/2016)... , Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC ... a 1-for-100 reverse split of its issued and outstanding ... trading on Thursday, February 11, 2016. The Company,s common ... CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After ... under the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology: